Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-db/db obese mice

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Shimizu, Masahito ^a   Yasuda, Yoichi ^a   Sakai, Hiroyasu ^a   Kubota, Masaya ^a   Terakura, Daishi ^a   Baba, Atsushi ^a   Ohno, Tomohiko ^a   Kochi, Takahiro ^a   Tsurumi, Hisashi ^a   Tanaka, Takuji ^b   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMP ACTIVATED KINASE ALPHA; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; DIETHYLNITROSAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 6; PITAVASTATIN; PROTEIN BAD; PROTEIN BCL 2; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ADIPONECTIN; ADIPONECTIN, MOUSE; AMPK ALPHA1 SUBUNIT, MOUSE; BAD PROTEIN, MOUSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEPTIN; LIPID; QUINOLINE DERIVATIVE;

ADIPONECTIN BLOOD LEVEL; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER PREVENTION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; FATTY LIVER; GENE EXPRESSION; GROWTH INHIBITION; HYPERLIPIDEMIA; LIPID STORAGE; LIVER; LIVER TUMOR; MALE; MOUSE; NONHUMAN; OBESITY; PRECANCER; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; TUMOR NECROSIS FACTOR ALPHA BLOOD LEVEL; ANIMAL; APOPTOSIS; BIOSYNTHESIS; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; COCARCINOGENESIS; CROSS BREEDING; DRUG EFFECT; DRUG SCREENING; DYSLIPIDEMIA; GENE EXPRESSION REGULATION; GENETICS; LIVER DISEASE; METABOLISM; MOUSE MUTANT; ORGAN SIZE; PATHOLOGY;

ADIPONECTIN; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; COCARCINOGENESIS; CROSSES, GENETIC; DIETHYLNITROSAMINE; DRUG SCREENING ASSAYS, ANTITUMOR; DYSLIPIDEMIAS; FATTY LIVER; GENE EXPRESSION REGULATION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-6; LEPTIN; LIPIDS; LIVER; LIVER DISEASES; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; ORGAN SIZE; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS C-BCL-2; QUINOLINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79959591727     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-281     Document Type: Article

References (43)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576. 10.1053/j.gastro.2007.04.061, 17570226.
2. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126:460-468. 10.1053/j.gastro.2003.10.065, 14762783.
3. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, Kato M, Nakamura T, Higuchi K, Nishiguchi S, Kumada H, Ohashi Y, . for the Long-Term Survival Study (LOTUS) Group Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 2006, 35:204-214. for the Long-Term Survival Study (LOTUS) Group.
4. Imai K, Takai K, Nishigaki Y, Shimizu S, Naiki T, Hayashi H, Uematsu T, Sugihara J, Tomita E, Shimizu M, Nagaki M, Moriwaki H. Insulin resistance raises the risk for recurrence of stage I hepatocellular carcinoma after curative radiofrequency ablation in hepatitis C virus-positive patients: A prospective, case series study. Hepatol Res 2010, 40:376-382. 10.1111/j.1872-034X.2009.00616.x, 20236359.
5. Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology 2005, 42:5-13.
6. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009, 115:5651-5661. 10.1002/cncr.24687, 19834957.
7. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010, 140:197-208. 10.1016/j.cell.2009.12.052, 2836922, 20141834.
8. Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, Destefanis G, Delogu S, Zimmermann A, Ericsson J, Brozzetti S, Staniscia T, Chen X, Dombrowski F, Evert M. Increased Lipogenesis, Induced by AKT-mTORC1-RPS6 Signaling, Promotes Development of Human Hepatocellular Carcinoma. Gastroenterology 2011, 140:1071-1083. 10.1053/j.gastro.2010.12.006, 21147110.
9. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010, 51:1820-1832. 10.1002/hep.23594, 20432259.
10. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009, 49:306-317. 10.1002/hep.22603, 2766096, 19065650.
11. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, . Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278. Cholesterol Treatment Trialists' (CTT) Collaborators.
12. Loria P, Lonardo A, Bellentani S, Day CP, Marchesini G, Carulli N. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis 2007, 17:684-698. 10.1016/j.numecd.2007.01.007, 17560098.
13. Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M, Ishitobi T, Nonaka M, Chayama K. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008, 57:1711-1718. 10.1016/j.metabol.2008.07.030, 19013295.
14. Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007, 47:135-141. 10.1016/j.jhep.2007.02.013, 17400325.
15. Egawa T, Toda K, Nemoto Y, Ono M, Akisaw N, Saibara T, Hayashi Y, Hiroi M, Enzan H, Onishi S. Pitavastatin ameliorates severe hepatic steatosis in aromatase-deficient (Ar-/-) mice. Lipids 2003, 38:519-523. 10.1007/s11745-003-1093-x, 12880107.
16. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005, 5:930-942. 10.1038/nrc1751, 16341084.
17. Gauthaman K, Fong CY, Bongso A. Statins, stem cells, and cancer. J Cell Biochem 2009, 106:975-983. 10.1002/jcb.22092, 19224538.
18. El-Serag HB, Johnson ML, Hachem C, Morgana RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009, 136:1601-1608. 10.1053/j.gastro.2009.01.053, 2677134, 19208359.
19. Sutter AP, Maaser K, Hopfner M, Huether A, Schuppan D, Scherubl H. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. J Hepatol 2005, 43:808-816. 10.1016/j.jhep.2005.04.010, 16083991.
20. Wang J, Tokoro T, Higa S, Kitajima I. Anti-inflammatory effect of pitavastatin on NF-kappaB activated by TNF-alpha in hepatocellular carcinoma cells. Biol Pharm Bull 2006, 29:634-639. 10.1248/bpb.29.634, 16595893.
21. Yasuda Y, Shimizu M, Shirakami Y, Sakai H, Kubota M, Hata K, Hirose Y, Tsurumi H, Tanaka T, Moriwaki H. Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Cancer Sci 2010, 101:1701-1707. 10.1111/j.1349-7006.2010.01579.x, 20398056.
22. Iwasa J, Shimizu M, Shiraki M, Shirakami Y, Sakai H, Terakura Y, Takai K, Tsurumi H, Tanaka T, Moriwaki H. Dietary supplementation with branched-chain amino acids suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. Cancer Sci 2010, 101:460-467. 10.1111/j.1349-7006.2009.01402.x, 19906067.
23. Frith CH, Ward JM, Turusov VS. Tumours of the liver. Pathology of Tumors in Laboratory Animals 1994, 2:223-270. Lyon: IARC Scientific Publications, Turusor VS, Mohr U.
24. Grimm C, Wenzel A, Hafezi F, Reme CE. Gene expression in the mouse retina: the effect of damaging light. Mol Vis 2000, 6:252-260.
25. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957, 226:497-509.
26. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007, 8:774-785. 10.1038/nrm2249, 17712357.
27. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009, 9:563-575. 10.1038/nrc2676, 2756045, 19629071.
28. Huang CH, Tsai SJ, Wang YJ, Pan MH, Kao JY, Way TD. EGCG inhibits protein synthesis, lipogenesis, and cell cycle progression through activation of AMPK in p53 positive and negative human hepatoma cells. Mol Nutr Food Res 2009, 53:1156-1165. 10.1002/mnfr.200800592, 19662644.
29. Teraoka N, Mutoh M, Takasu S, Ueno T, Yamamoto M, Sugimura T, Wakabayashi K. Inhibition of intestinal polyp formation by pitavastatin, a HMG-CoA reductase inhibitor. Cancer Prev Res 2011, 4:445-453.
30. Aoki T, Nishimura H, Nakagawa S, Kojima J, Suzuki H, Tamaki T, Wada Y, Yokoo N, Sato F, Kimata H, Kitahara M, Toyoda K, Sakashita M, Saito Y. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittelforschung 1997, 47:904-909.
31. Sata M, Nishimatsu H, Osuga J, Tanaka K, Ishizaka N, Ishibashi S, Hirata Y, Nagai R. Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension 2004, 43:1214-1220. 10.1161/01.HYP.0000126186.29571.41, 15166180.
32. Kita T, Brown MS, Goldstein JL. Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. J Clin Invest 1980, 66:1094-1100. 10.1172/JCI109938, 371547, 6903572.
33. Yasui Y, Suzuki R, Miyamoto S, Tsukamoto T, Sugie S, Kohno H, Tanaka T. A lipophilic statin, pitavastatin, suppresses inflammation-associated mouse colon carcinogenesis. Int J Cancer 2007, 121:2331-2339. 10.1002/ijc.22976, 17657716.
34. Hector J, Schwarzloh B, Goehring J, Strate TG, Hess UF, Deuretzbacher G, Hansen-Algenstaedt N, Beil FU, Algenstaedt P. TNF-alpha alters visfatin and adiponectin levels in human fat. Horm Metab Res 2007, 39:250-255. 10.1055/s-2007-973075, 17447161.
35. Finck BN, Johnson RW. Anti-inflammatory agents inhibit the induction of leptin by tumor necrosis factor-alpha. Am J Physiol Regul Integr Comp Physiol 2002, 282:R1429-1435.
36. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007, 380:24-30. 10.1016/j.cca.2007.01.026, 2755046, 17343838.
37. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003, 112:91-100. 162288, 12840063.
38. Kamada Y, Matsumoto H, Tamura S, Fukushima J, Kiso S, Fukui K, Igura T, Maeda N, Kihara S, Funahashi T, Matsuzawa Y, Shimomura I, Hayashi N. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol 2007, 47:556-564. 10.1016/j.jhep.2007.03.020, 17459514.
39. Saxena NK, Fu PP, Nagalingam A, Wang J, Handy J, Cohen C, Tighiouart M, Sharma D, Anania FA. Adiponectin Modulates C-Jun N-Terminal Kinase and Mammalian Target of Rapamycin and inhibits hepatocellular carcinoma. Gastroenterology 2010, 139:1762-1773. 10.1053/j.gastro.2010.07.001, 2967590, 20637208.
40. Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither?. Hepatology 2008, 48:662-669. 10.1002/hep.22402, 18666246.
41. Targher G, Bertolini L, Padovani R, Rodella S, Arcaro G, Day C. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 2007, 46:1126-1132. 10.1016/j.jhep.2007.01.021, 17335930.
42. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, Nakamura T, Kojima T. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996, 334:1561-1567. 10.1056/NEJM199606133342402, 8628336.
43. Shimizu M, Sakai H, Shirakami Y, Iwasa J, Yasuda Y, Kubota M, Takai K, Tsurumi H, Tanaka T, Moriwaki H. Acyclic retinoid inhibits diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. Cancer Prev Res 2011, 4:128-136.